Although CAR-T cells are effective in hematologic malignancies, their activity in NSCLC is limited by antigen heterogeneity, dysfunction induced by the TME, and inhibitory signaling mediated by PD-1. Here, PDCD1 is linked to non-small cell lung carcinoma.